Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 2/3 2Phase 1/2 2Phase NA 1Phase 4 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × peginterferon alfa-2b × Clear all
NCT00522249 2016-03-17

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

The Methodist Hospital Research Institute

Phase 1/2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00085384 2012-08-02

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡